Sentence examples for most common anticancer from inspiring English sources

The most common anticancer drug administered for NSCLC is paclitaxel (PTX).

These results indicate that TNF-induced signaling may be the most common anticancer drug or chemical compound-triggered cell death program.

The majority of IRMA patients were also receiving nephrotoxic anticancer agents at the time of the study; the most common anticancer drugs prescribed were 5-FU, cyclophosphamide, docetaxel, epirubicin, and gemcitabine.

The most common prior anticancer therapies for MCL patients (single-agent or in combination) were rituximab (97%), cyclophosphamide (93%), vincristine (90%), doxorubicin (84%), prednisone (65%), etoposide (42%), cytarabine (35%), and bortezomib (32%).> -wrap-foot> Efficacy was measured by local investigators and central reviewers for all patients (Table 2).

The most two common anticancer inhibitors are anilinoquiazolines and anilinoquinolines that inhibit EGFR kinase intracellularly.

The most common post-study anticancer therapy overall was everolimus (12.5% for both groups), but a markedly greater proportion of patients in the nintedanib vs sunitinib group received interferon (14.1% vs 3.1%).

Moreover, because these processes have been well conserved between yeast and humans, these investigators used a panel of up to 70 isogenic strains, each defective in either DNA repair or cell cycle control gene/genes, for the systematic testing of the 33 most common FDA-approved anticancer cytotoxic drugs (Hartwell et al, 1997; Simon et al, 2000).

First, we designed an indirect HTRF assay on a microtiter plate format and demonstrated its general applicability through the analysis of the interactions between MutS and mismatched DNA or DNA containing the most common lesion of the anticancer drug cisplatin.

The most common side effects of anticancer treatment include vasospastic and thromboembolic ischemia, arterial hypertension, arrhythmia, and cardiac dysfunction up to heart failure (HF) [ 1, 2].

The overexpression of three major ABC drug transporters is the most common mechanism for acquired resistance to anticancer drugs.

This is not surprising since the overexpression of ABC transporters is one of the most common mechanisms of acquired resistance to anticancer agents.